Best Life Sciences Tech Companies in China
The 91 best Life Sciences Tech companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abogen Biosciences.
China's Life Sciences Tech sector isn't waiting around. Our directory tracks 91 companies across China with $2.6B in total disclosed funding, and the concentration at the top tells you something real: Abogen Biosciences alone accounts for $1.1B of that, with DeepWise at $46M and Leman Biotech at $43M rounding out a top tier that's pulling hard from investors like Hillhouse, Legend Capital, and 5Y Capital. Three unicorns have emerged from this cohort already. And median install growth of roughly +43% YoY across life sciences and healthcare apps signals that digital adoption isn't a talking point, it's a measurable fact, one LifeSciencesIntelligence has been tracking as the sector scales globally past early benchmarks. So what's actually moving right now?
Drug repurposing via AI, device-biologic combinations, and wearable biotech are the themes I keep seeing surface across funding rounds and product announcements this quarter. Pharma digital strategy is no longer a side project for R&D teams, it's the whole conversation. Regulatory compliance pressure in China adds another layer, pushing companies to build with compliance architecture from day one rather than retrofitting it later. If you're trying to place a bet or a partnership in this space, the funding momentum here is worth reading carefully, because the companies ranked below represent where serious capital is already going.
- EVERSANA
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Tech companies in China
| # | Company | Disclosed funding | Last round | Stage | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Abogen Biosciences 🦄 Developer of mRNA-based therapeutics for cancer and infectious diseases 55Moat top 14%Patents top 17%Innovation top 22%Funding top 27% All 8 signals ▾Moattop 14% Patentstop 17% Innovationtop 22% Fundingtop 27% Talenttop 38% Marketbottom 44% Globalbottom 43% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $1.1B | 49 mo ago | Series C | 2019 | Dr InBev Co-Founder & Co-CEO | 157 patents mRNA and circular RNA therapeutics with lipid nanoparticle delivery systems | — |
| 2 | ICarbonX 🦄 Provider of bioinformatic platforms for health management and drug development 67Moat top 26%Funding top 27%Talent top 28%AI top 30% All 8 signals ▾Moattop 26% Fundingtop 27% Talenttop 28% AItop 30% Markettop 38% Globalbottom 48% Newsbottom 27% Techbottom 21% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $366M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $366M | 62 mo ago | Series D | 2015 | Yingrui Li Co-Founder & Chief Scientist | — | 2 partnerships |
| 3 | LinkDoc 🦄 Provider of the oncology-focused database 76Moat top 15%AI top 20%Market top 25%Product top 26% All 10 signals ▾Moattop 15% AItop 20% Markettop 25% Producttop 26% Innovationtop 27% Fundingtop 31% Talentbottom 49% Globalbottom 38% Newsbottom 27% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · Unicorn AI: Classified as an AI company rank vs industry peers · Fliar Intelligence Index 76/100 | $263M | 63 mo ago | Series D | 2014 | Tony Zhang Founder & CEO | — | — |
| 4 | NeoCura Provider of an AI-enabled immunotherapy based tumor diagnostic platform | $117M | 54 mo ago | Series A | 2017 | Wang Yi Co-Founder & CEO | — | — |
| 5 | Xbiome Developer of an AI-enabled bioinformatics platform for the discovery of drugs using intestinal microbiome 64AI top 20%Funding top 36%Moat top 38%Market top 49% All 5 signals ▾AItop 20% Fundingtop 36% Moattop 38% Markettop 49% Globalbottom 36% AI: Classified as an AI company Funding: Raised $108M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $108M | 54 mo ago | Series B | 2017 | — | — | — |
| 6 | Triastek Provider of 3D printing pharmaceutical technology platform for drug design 69Innovation top 15%Patents top 18%Funding top 31%Moat top 37% All 8 signals ▾Innovationtop 15% Patentstop 18% Fundingtop 31% Moattop 37% Talenttop 38% Marketbottom 45% Globalbottom 40% Newsbottom 22% Innovation: 196 patents (top 7% of patent-holders) · 125 filings since 2022 vs 68 in 2017-21 Patents: 196 patents matched (strict assignee match) · 125 filings since 2022 vs 68 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $102M | 32 mo ago | Series B | 2015 | Xiaoling Li Co-Founder | 196 patents Advanced pharmaceutical dosage forms and additive manufacturing for controlled-release capsules | — |
| 7 | StoneWise Provider of a software solution solution for molecular modeling | $100M | 62 mo ago | Series B | 2018 | Zhou Jielong Founder & CEO | — | — |
| 8 | HeliXon Developer of an integrated platform for protein therapeutic discovery and optimization | $75M | 48 mo ago | Series A | 2009 | Zhu Zhenping Co-CEO | — | — |
| 9 | DeepWise Developer of AI-based radiology image solutions primarily for cancer diagnosis 72AI top 26%Funding top 30%Market top 35%Moat top 39% All 5 signals ▾AItop 26% Fundingtop 30% Markettop 35% Moattop 39% Globalbottom 36% AI: Classified as an AI company · Product described with: ai-based, deep learning Funding: Raised $46.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $46M | 16 mo ago | Series D | 2017 | — | — | — |
| 10 | Leman Biotech Develope rof AI-based platform for cancer immunotherapy 21AI top 30%Talent top 38%Funding top 39%Global bottom 29% All 6 signals ▾AItop 30% Talenttop 38% Fundingtop 39% Globalbottom 29% Marketbottom 25% Techbottom 15% AI: Classified as an AI company · Product described with: ai-based Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $43M | 3 mo ago | Series A | 2021 | Li Tang Co-Founder | — | — |
| 11 | neoX Biotech Provider of research and characterization of protein-protein interactions to facilitate drug discovery | $40M | 59 mo ago | Series A | 2018 | Fan Liu Co-Founder | — | — |
| 12 | Hugo Biotech Developer of cloud-based pathogenic microorganism data analysis system | $34M | 68 mo ago | Series A | 2017 | Han Xia Founder & CEO | — | — |
| 13 | MindRank Provider of AI-based drug candidate identification solutions for drug development 64Innovation top 19%Patents top 26%AI top 30%Moat top 38% All 8 signals ▾Innovationtop 19% Patentstop 26% AItop 30% Moattop 38% Fundingtop 40% Talentbottom 49% Marketbottom 40% Globalbottom 31% Innovation: 47 patents (top 23% of patent-holders) · 47 filings since 2022 vs 0 in 2017-21 Patents: 47 patents matched (strict assignee match) · 47 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $30M | 35 mo ago | Series A | 2019 | Zhangming Niu Founder & CEO | 47 patents Novel GLP‑1 receptor agonist polymorphs/salts and kinase inhibitor heterocycles for therapeutics | — |
| 14 | Deep Intelligent Pharma Developer of AI-based drug development platform 62Funding top 26%Talent top 28%AI top 30%Moat top 39% All 7 signals ▾Fundingtop 26% Talenttop 28% AItop 30% Moattop 39% Marketbottom 49% Techbottom 43% Globalbottom 29% Funding: Raised $21.6M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 62/100 | $22M | 4 mo ago | Series E | 2017 | — | — | — |
| 15 | Silexon Virtual high throughput screening based drug discovery platform | $15M | 57 mo ago | Deadpooled | 2018 | Hainian Zeng CEO | — | — |
| 16 | Besun Biotechnology Developer of a synthetic biology-based platform for drug discovery | $15M | 46 mo ago | Seed | — | Kang Kang Co-Founder | — | — |
| 17 | Molecular Heart Provider of chemoproteomics platform for small molecule drug discovery 24AI top 26%Funding top 38%Talent bottom 49%Tech bottom 30% All 6 signals ▾AItop 26% Fundingtop 38% Talentbottom 49% Techbottom 30% Globalbottom 29% Marketbottom 25% AI: Classified as an AI company · Product described with: ai-based, deep learning Funding: Raised $14.6M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $15M | 21 mo ago | Series A | 2022 | Xu Jinbo Founder | — | 1 launch |
| 18 | Pharmacodia Online database solutions for pharmaceutical R&D | $15M | 93 mo ago | Series B | 2013 | Hongxia Ding Founder & CEO | — | — |
| 19 | Shanghai Tianyu Technology Provider of an AI-powered protein design model 42AI top 30%Funding top 36%Talent bottom 49%Market bottom 37% All 5 signals ▾AItop 30% Fundingtop 36% Talentbottom 49% Marketbottom 37% Globalbottom 29% AI: Classified as an AI company · Product described with: ai-powered Funding: Raised $13.8M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $14M | 19 mo ago | Series A | 2021 | Liang Hong Founder | — | — |
| 20 | Galixir AI-based molecular drug development tool | $10M | 58 mo ago | Seed | 2019 | Chengtao Li Co-Founder & CEO | — | — |
| 21 | ForceClouds Sales automation SaaS provider for Life Sciences Industry | $10M | 78 mo ago | Series B | 2015 | Jeff Meng Co-Founder | — | — |
| 22 | eDoctor Pharmaceutical marketing and promotion solutions for healthcare enterprises | $10M | 126 mo ago | Series A | 2004 | — | — | — |
| 23 | Zhinuvis Provider of AI based tools for tumor gene and pathology analysis | $9M | 79 mo ago | Series B | 2015 | Ling Shaoping Founder & CEO | — | — |
| 24 | Perpetual Medicines Provider of computational design and synthesis platform for peptide drug discovery | $8M | 30 mo ago | Seed | 2023 | Kerry Blanchard Co-Founder & CEO | — | — |
| 25 | AIxplorerBio AI-based drug development tool for providers | $8M | 61 mo ago | Series A | 2021 | David Xu Founder & CEO | — | — |
| 26 | Beijing Zechuang Tiancheng Biomedical Technology Developer of clinical research learning and collaboration platform | $3M | 70 mo ago | Seed | 2015 | — | — | — |
| 27 | Beijing Medical Hua Mobile Medical Technology Provider of a platform for medical information | $2M | 90 mo ago | Series A | 2016 | Shen Yanli Founder & CEO | — | — |
| 28 | GigaCeuticals AI enabled platform for drug discovery | $2M | 51 mo ago | Seed | 2018 | Zhengwei Xie Founder & CEO | — | — |
| 29 | Gongyingshi B2B procurement platform for R&D labs | $2M | 113 mo ago | Series B | 2014 | — | — | — |
| 30 | iLabService IoT and AI enabled lab operations management solutions | $120K | 58 mo ago | Series A | 2016 | Jing Wang Co-Founder & COO | — | — |
Top 12 Life Sciences Tech companies in China
#1
Series A · Shenzhen, Guangdong Province · founded 2021$42.9Mraised▾
Develope rof AI-based platform for cancer immunotherapy. It provides a Meta 10 Metabolism-enhanced cell treatment platform that encourages the metabolic reprogramming of exhausted T lymphocytes by oxidative phosphorylation, restoring their ability to proliferate and kill malignancies.
- Mar 2026Series A$29M
- Nov 2024Series A$13.9M
#2
Series E · Chaoyang, Beijing · founded 2017 · 100 employees$21.6Mraised▾
Beijing Shenzhi Yao Technology is developing AI-based drug development platform. They have developed their multi-language drug development platform which provides services including drug discovery solutions, medical writing, regulatory support, electronic data acquisition system, clinical data programming, and clinical data management support. Few clients of the company include Roche, GSK, Bayer, etc.
- Feb 2026Series E$60M
- Dec 2025Series D$50M
- Oct 2018Series B$15M
#3
Series D · Beijing, Beijing · founded 2017 · 200 employees$46.3Mraised▾
DeepWise is a developer of AI-based radiology image solutions primarily for cancer diagnosis. Its solution uses a deep learning framework to assist in medical imaging diagnosis. Claims to help in the diagnosis of breast cancer, stroke, emergency fracture, prostate cancer, and lung cancer. The company offers the cloud-based image platform, and also helps in clinical decision making and research.
- Feb 2025Series D$68.6M
- May 2021Series C—
- Dec 2020Series C—
- Jun 2019Series C—
#4
Series A · Minhang, Shanghai · founded 2021$13.8Mraised▾
Provider of an AI-powered protein design model. It offers AccelProtein a self-developed large-scale AI protein design model that caters to various applications including antibodies, nutrition, vaccines, food & drink, among others.
- Nov 2024Series A$13.8M
- Mar 2024Seed—
#5
Series C · Suzhou, Jiangsu · founded 2019$1.1Braised▾
Developer of mRNA-based therapeutics for cancer and infectious diseases. The company has developed proprietary technology platforms in mRNA design, in vitro synthesis, and LNP-based delivery systems to develop targeted therapies for infectious and immuno-oncology indications.
- May 2022Series C—
- Nov 2021Series C$300M
- Aug 2021Series C$720M
- Apr 2021Series B$91.6M
#6
Series A · Beijing, Beijing · founded 2022$14.6Mraised▾
Provider of chemoproteomics platform for small molecule drug discovery. The company has created an AI-based macromolecular optimization and design platform "MoleculeOS" with uses data-driven deep learning methods to help biotechnologists quickly identify and generate the most suitable proteins and rapidly project laboratory research results on a large scale for industrial applications.
- Sep 2024Series A—
- Feb 2023Angel$14.6M
#7
Series B · Nanjing, Jiangsu · founded 2015 · 46 employees$102.3Mraised▾
Provider of 3D printing pharmaceutical technology platform for drug design. The company focuses on the development of 3D bioprinters and Melt Extrusion Deposition (MED) 3D printing technology for dosage form design, and digital pharmaceutical product development.
- Sep 2023Series B$20.4M
- Jun 2021Series B$51M
- Dec 2020Series A$15.3M
- Jun 2018Series A$15.6M
#8
ICarbonX 🦄Series D · Shenzhen, Guangdong Province · founded 2015 · 300 employees$365.7Mraised▾
iCarbonX provides a bioinformatics platform for health management and drug development. It plans to use big data and artificial intelligence to analyze omic data along with phenotypic, social, and environmental information. The analysis would be used by individuals for health management and by pharma companies for drug development. Solutions offered are Hey me, Healthtell immune response chip, and DigitalMe. Hey me is a digital health management platform that features genetic testing, sports data tracking, prediction, customized sports programs, personalized beauty products according to skin type, personalized dietary plans. DigitalMe is a health platform that tracks the health of patients suffering from chronic disease.
- Apr 2021Series D$151M
- 2018Series A—
- Jul 2016Series A$45M
- Apr 2016Series A$154.7M
#9
LinkDoc 🦄Series D · Haidian, Beijing · founded 2014 · 1250 employees$263.3Mraised▾
Provider of the oncology-focused database. It is a big data company that is involved in medical information systems integration and application software development. It claims to have built a rich repository of cancer patients' medical records and comprehensive clinical data. It empowers evidence-based, personalized cancer treatment in China by providing doctors with valuable analytics derived from its oncology database.
- Mar 2021Series D—
- Sep 2020Series D$102.3M
- Jul 2018Series D$151M
- Apr 2016Series B—
#10
Series A · Shanghai, Shanghai · founded 2019$30Mraised▾
Provider of AI-based drug candidate identification solutions for drug development. The platform enables researchers and pharma industries for identification, virtual screening, and prediction of drug molecule properties for the R & D process.
- Jul 2023Series A$23M
- Dec 2021Series A—
- May 2021Seed$7M
#11
Series B · Shenzhen, Guangdong Province · founded 2017 · 63 employees$107.5Mraised▾
Developer of an AI-enabled bioinformatics platform for the discovery of drugs using intestinal microbiome. The company uses Fecal microbiota transplantation (FMT) technology for the development of drugs for multiple diseases. It includes extraction of microbiota from the stool of healthy people through various methods and then transplant it into patients and used to treat various diseases.
- Dec 2021Series B$100M
- Dec 2020Series B—
- Nov 2019Series B—
- Jun 2019Series A—
#12
Series A · Changping, Beijing Shi · founded 2017$116.6Mraised▾
NeoCura has developed cancer therapeutic AI-based platforms and diagnostic tests. The company's AI-based integrated platform uses molecular and clinical data for diagnosing cancer. The precision medicine products developed are NeoCura for cancer detection from blood, NeoCura Vac is an AI-guided neoantigen therapeutics, and NeoCura Info is an AI bioinformatics service for multi-omics analysis.
- Dec 2021Series A—
- Dec 2020Series A$38.2M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in China
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 5,865 China-affiliated papers.
- Chinese Academy of Sciences263
- Chinese Academy of Agricultural Sciences227
- Ministry of Agriculture and Rural Affairs168
- China Agricultural University159
- Huazhong Agricultural University138
- Gene4→218
- Gene knockdown3→73
- Transcriptome1→62
- Detection limit1→59
- Mutant3→56
- Gene9→275
- Gene knockdown1→166
- Downregulation and upregulation2→161
- Apoptosis6→129
- Transcription factor3→77
- Agriculture6→68
- Antibiotic resistance1→43
- Resistance (ecology)2→33
- Gene2→32
- Synthetic biology1→30
Where biotechnology is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in China
China biotechnology patent filing is accelerating — 58,925 filings from 8,000 assignees (2016–2025), led by Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine, UNIV Jiangnan; annual filings 1737→10545.
- Shanghai Hengrui Pharmaceutical1154
- Jiangsu Hengrui Medicine1027
- UNIV Jiangnan1000
- Innovent Biologics Suzhou666
- UNIV Tsinghua627
- Jiangsu Hengrui Pharmaceuticals594
- UNIV Xiamen575
- UNIV Beijing549
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.